Neurodegenerative disease profoundly affects structures and pathways responsible for memory, cognition, and higher-order ...
Alzheimer disease (AD) is the most common cause of dementia and one of the leading causes of death in adults age 65 y or ...
The approval of disease-modifying antiamyloid therapies has expanded the clinical role of amyloid PET beyond diagnostic confirmation to include baseline characterization and longitudinal monitoring of ...
Amyloid PET has become a pivotal imaging biomarker for Alzheimer disease (AD), enabling in vivo detection and quantification of β-amyloid deposition. However, variability in quantitative measurements ...
The growing demand for amyloid and tau PET imaging, driven by new dementia therapies and biomarker-based diagnosis, has increased the need for accessible PET brain imaging in outpatient neurology ...
Journal of Nuclear Medicine Technology February 2026, jnmt.125.271265; DOI: https://doi.org/10.2967/jnmt.125.271265 ...
Journal of Nuclear Medicine Technology February 2026, jnmt.125.271428; DOI: https://doi.org/10.2967/jnmt.125.271428 ...
Journal of Nuclear Medicine Technology February 2026, jnmt.125.271835; DOI: https://doi.org/10.2967/jnmt.125.271835 ...
Neurodegenerative diseases are characterized by progressive neuronal dysfunction, synaptic loss, and decline in cognitive, behavioral, or motor function. Understanding these disorders requires a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results